Researchers and startups are applying foundation models to reduce variability in stem‑cell derived therapeutics while investors back AI‑native lab platforms. An AI foundation model targeting prediction and control of stem cell differentiation was described alongside Phylo’s $13.5 million seed raise to commercialize Biomni Lab, an integrated AI‑enabled environment for experimental design and execution. The combination signals growing investor conviction that AI orchestration can compress preclinical timelines and improve reproducibility for cell therapies.